Skip to nav Skip to content
Philippe  Spiess

Philippe Spiess, MD

Program: Genitourinary Oncology

Research Program: Cancer Epidemiology Program

Contact

  • Overview

    My main areas of research interests include developing novel therapeutic agents in the management of locally advanced and metastatic renal carcinoma.

    Associations

    • Genitourinary Oncology
    • Tumor Microenvironment and Metastasis
    • Center for Immunization & Infection Research in Cancer
    • Cancer Chemoprevention Research Interest Group
    • Cancer Epidemiology Program

    Education & Training

    Graduate:

    • McGill University, Montreal, Canada, MS - Experimental Surgery, Urology

    Board Certification:

      Fellowship:

      • University of Texas MD Anderson Cancer Center, Houston, TX - Urologic Oncology

      Residency:

      • McGill University, Montreal, Canada - Urology

      Medical School:

      • University of Toronto, Ontario, Canada - MD
    • Research Interest

      My main areas of research interests include developing novel therapeutic agents in the management of locally advanced and metastatic renal carcinoma. As well, I have interests in developing multi-modality therapeutic strategies in the management of locally advanced and locally recurrent prostate cancer, with the aim of optimizing treatment outcomes while minimizing morbidity.

    • Participating Trials

      Clinical Trial 19319
      InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
      Condition: Genitourinary
      Intervention: Ifosfamide (); Not Applicable (); Radiotherapy (); Taxol (paclitaxel); cisplatin (); paclitaxel ()
      Status: Open

      If you believe you are eligible for one of these trials or studies, please call
      813-745-6100 or toll-free 1-800-679-0775.

    • Publications

      • Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2024 Mar.85(3):283-292. Pubmedid: 37802683.
      • Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol E, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol. 2024 Mar.37(3):100424. Pubmedid: 38219954.
      • von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein MW, Lonati C, Crocetto F, Taylor J, Tully KH, Afferi L, Soria F, Del Giudice F, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, Lotan Y, Spiess PE, Black PC, Kiss B, Pradere B, Shariat SF. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. BJU Int. 2024 Mar.133(3):341-350. Pubmedid: 37904652.
      • Sachdeva A, McGuinness L, Zapala Ł, Greco I, Garcia-Perdomo HA, Kailavasan M, Antunes-Lopes T, Ayres B, Barreto L, Campi R, Crook J, Johnstone P, Kumar V, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Protzel C, Bryan Rumble R, Sánchez Martínez DF, Spiess PE, Tagawa ST, van der Heijden MS, Parnham AS, Pettaway CA, Albersen M, Sangar VK, Brouwer OR, Sakalis VI. Management of Lymph Node-positive Penile Cancer: A Systematic Review. Eur Urol. 2024 Mar.85(3):257-273. Pubmedid: 37208237.
      • Huang J, Chan SC, Pang WS, Liu X, Zhang L, Lucero-Prisno DE, Xu W, Zheng ZJ, Ng AC, Necchi A, Spiess PE, Teoh JY, Wong MC. Incidence, risk factors, and temporal trends of penile cancer: a global population-based study. BJU Int. 2024 Mar.133(3):314-323. Pubmedid: 37953505.
      • Shiver L, Sirard R, Spiess PE, Khan F, Manley BJ, Wang C, Zemp L, Bassil C, Huelster HL. Short- and Long-Term Renal Function After Partial Nephrectomy: Comparison of Solitary and Multifocal Renal Masses. Urol Pract. 2024 Mar.11(2):347-355. Pubmedid: 38154008.
      • Ionescu F, Nguyen J, Segura CM, Paravathaneni M, Grass GD, Johnstone P, Zacharias NM, Pettaway CA, Lu X, Kim Y, Whiting J, Dhillon J, Eschrich SA, Chadha J, Gullapalli K, Roman Souza G, Miyagi H, Manley BJ, Spiess PE, Chahoud J. Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage. Cancers (Basel). 2024 Jan.16(2). Pubmedid: 38275860. Pmcid: PMC10814242.
      • Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jan. Pubmedid: 38184473.
      • Vreeburg MTA, Donswijk ML, Albersen M, Parnham A, Ayres B, Protzel C, Pettaway C, Spiess PE, Brouwer OR. New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective. Eur J Nucl Med Mol Imaging. 2024 Jan. Pubmedid: 38216778.
      • Youssef I, Elst L, Watkin N, de Vries HM, Brouwer O, Protzel C, Ayres B, Albersen M, Spiess PE, Johnstone PAS. International case series of metastasis to penis. BJUI Compass. 2024 Jan.5(1):166-169. Pubmedid: 38179026. Pmcid: PMC10764158.
      • Brouwer OR, Rumble RB, Ayres B, Sánchez Martínez DF, Oliveira P, Spiess PE, Johnstone PAS, Crook J, Pettaway CA, Tagawa ST. Penile Cancer: EAU-ASCO Collaborative Guidelines Update Q and A. JCO Oncol Pract. 2024 Jan.20(1):33-37. Pubmedid: 37956391.
      • Suk-Ouichai C, Coghill AE, Schabath MB, Sanchez JA, Chahoud J, Necchi A, Giuliano AR, Spiess PE. A clinical overview of people living with HIV and genitourinary cancer care. Nat Rev Urol. 2024 Jan. Pubmedid: 38238527.
      • O'Connell KA, Thomas JL, Murad F, Zhou G, Sonpavde GP, Mossanen M, Clinton TN, Ji-Xu A, Alton K, Spiess PE, Rossi AM, Schmults CD. Total Margin Control Is Superior to Traditional Margin Assessment for Treatment of Low-Stage Penile Squamous Cell Carcinoma. J Urol. 2024 Jan.211(1):90-100. Pubmedid: 37788015. Pmcid: PMC10841097.
      • Paravathaneni M, Safa H, Joshi V, Tamil MK, Adashek JJ, Ionescu F, Shah S, Chadha JS, Gilbert S, Manley B, Semaan A, Jim HSL, Kalos D, Kim Y, Spiess PE, Chahoud J. 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. EClinicalMedicine. 2024 Feb.68:102413. Pubmedid: 38273886. Pmcid: PMC10809115.
      • Hensley PJ, Labbate C, Zganjar A, Howard J, Huelster H, Durdin T, Pham J, Xiao L, Pallauf M, Lombardo K, Glezerman I, Singla N, Raman JD, Coleman J, Spiess PE, Margulis V, Potretzke AM, Matin SF. Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function. Eur Urol Oncol. 2024 Feb. Pubmedid: 38307832.
      • Rose KM, Pham R, Zacharias NM, Ionescu F, Paravathaneni M, Marchetti KA, Sanchez D, Mustasam A, Sandstrom R, Vikram R, Dhillon J, Rao P, Schneider A, Pagliaro L, Alifrangis C, Albersen M, Roussel E, Master VA, Nazha B, Hernandez C, Moses KA, Protzel C, Montgomery J, Angel M, Tobias-Machado M, Spiess PE, Pettaway CA, Chahoud J. Neoadjuvant Platinum-Based chemotherapy and lymphadenectomy for penile cancer: an international, Multi-Institutional, Real-World study. J Natl Cancer Inst. 2024 Feb. Pubmedid: 38366627.
      • Crupi E, de Padua TC, Marandino L, Raggi D, Dyrskjøt L, Spiess PE, Sonpavde GP, Kamat AM, Necchi A. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol Oncol. 2024 Feb.7(1):44-52. Pubmedid: 37330413.
      • Costa de Padua T, Sabino Marques Monteiro F, Necchi A, Spiess PE. Redefining Rare Genitourinary Cancers: An Initiative Led by the Global Society of Rare Genitourinary Tumors. Eur Urol. 2024 Feb. Pubmedid: 38403526.
      • Bakshi GK, Pal M, Jain DK, Arora A, Tamhankar A, Maitre P, Murthy V, J A, Agrawal A, Menon S, Joshi A, Spiess PE, Prakash GJ. Surgical templates for inguinal lymph node dissection in cN0 penile cancer: A comparative study. Urol Oncol. 2023 Sep.41(9):393.e9-393.e16. Pubmedid: 37507285.
      • Davaro F, Davaro E, Rose K, Murthy P, Naidu S, Camperlengo L, Grass GD, Vosoughi A, Jain RK, Zemp L, Yu A, Poch MA, Spiess PE, Gilbert SM, Sexton WJ, Li R. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):389.e7-389.e13. Pubmedid: 36959058.
      • Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J, Ross JS, Spiess PE. Immunotherapy in the Treatment of Localized Genitourinary Cancers. JAMA Oncol. 2023 Oct.9(10):1447-1454. Pubmedid: 37561425.
      • Hugar LA, Peak TC, Naqvi M, Kim Y, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Briganti A, Salvioni R, Chakiryan NH, Montorsi F, Necchi A, Spiess PE. Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care?. Urology. 2023 Oct.180:176-181. Pubmedid: 37467807.
      • Peak T, Spiess PE, Li R, Grivas P, Necchi A, Pavlick D, Huang RSP, Lin D, Danziger N, Jacob JM, Bratslavsky G, Ross JS. Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry. Oncologist. 2023 Oct.28(10):e910-e920. Pubmedid: 37196060. Pmcid: PMC10546831.
      • Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
      • Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, Waguespack SG, Kilkelly JE, Rednam S, Pruthi S, Jonasch EA, Baum L, Chahoud J. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 Oct.129(19):2927-2940. Pubmedid: 37337409.
      • Ho MD, Black AJ, Zargar H, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Vasdev N, Sridhar SS, McGrath JS, Aning J, Holzbeierlein JM, Thorpe AC, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy. Can Urol Assoc J. 2023 Oct.17(10):301-309. Pubmedid: 37851909. Pmcid: PMC10581722.
      • Elst L, Vreeburg MTA, de Vries HM, Vandermaesen K, Murphy T, Churchill J, Fallara G, Sanchez D, Falcone M, Garcia-Perdomo HA, Pettaway C, Hakenberg O, Johnstone P, Spiess PE, Muneer A, Sangar V, Parnham A, Ayres B, Watkin N, Brouwer OR, Albersen M. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. 2023 Oct. Pubmedid: 37813746.
      • Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
      • Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by. Eur Urol Oncol. 2023 Nov. Pubmedid: 38000932.
      • Myers AA, Briganti A, Leibovich B, Lerner SP, Moschini M, Rouprêt M, Shariat SF, Spiess PE, Stenzl A, Taneja SS, Touijer KA, Kamat AM. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?. Eur Urol Oncol. 2023 Nov. Pubmedid: 37980250.
      • Chatwal MS, Chahoud J, Spiess PE. Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma. Cancer Drug Resist. 2023 May.6(2):314-326. Pubmedid: 37457132. Pmcid: PMC10344725.
      • Davaro F, Spiess PE. Enlisting Urologists to Improve Palliative Care Services Integration in the Care of Advanced Penile Cancer. J Urol. 2023 May.209(5):824-826. Pubmedid: 36803025.
      • von Deimling M, Mertens LS, van Rhijn BWG, Lotan Y, Spiess PE, Daneshmand S, Black PC, Pallauf M, D'Andrea D, Moschini M, Soria F, Del Giudice F, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh JY, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz PI, Babjuk M, Gontero P, Xylinas E, Rink M, Shariat SF, Pradere B. Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer. Eur Urol Open Sci. 2023 May.51:39-46. Pubmedid: 37187719. Pmcid: PMC10175724.
      • Patel KB, Alishahi Tabriz A, Turner K, Gonzalez BD, Oswald LB, Jim HSL, Nguyen OT, Hong YR, Aldawoodi N, Cao B, Wang X, Rollison DE, Robinson EJ, Naso C, Spiess PE. Telemedicine Adoption in an NCI-Designated Cancer Center During the COVID-19 Pandemic: A Report on Patient Experience of Care. J Natl Compr Canc Ne. 2023 May.21(5):496-502.e6. Pubmedid: 37156477.
      • Kirk PS, Lotan Y, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 May.209(5):882-889. Pubmedid: 36795962.
      • Grass GD, Chahoud J, Lopez A, Dhillon J, Eschrich SA, Johnstone PAS, Spiess PE. An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma. Eur Urol Open Sci. 2023 Mar.49:1-5. Pubmedid: 36660545. Pmcid: PMC9843170.
      • Huelster HL, Chang A, Rose K, Bandini M, Albersen M, Roussel E, Chipollini J, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Marandino L, Pederzoli F, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Ahmed ME, Karnes JR, Briganti A, Kim Y, Montorsi F, Necchi A, Spiess PE. Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference?. J Urol. 2023 Mar.209(3):557-564. Pubmedid: 36652397.
      • Murthy PB, Naidu S, Davaro F, Spiess PE, Zemp L, Poch M, Jain R, Vosoughi A, Grass GD, Yu A, Sexton WJ, Gilbert SM, Li R. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Curr Oncol. 2023 Mar.30(3):3223-3231. Pubmedid: 36975458. Pmcid: PMC10046994.
      • Nguyen OT, Mason A, Khanna N, Charles D, Naso C, Hong YR, Sprow O, Alishahi Tabriz A, Turner K, Spiess P, Patel KB. Patient and caregiver experience with telehealth for surgical cancer care: A qualitative study. J Surg Oncol. 2023 Jun.127(7):1203-1211. Pubmedid: 36883752.
      • Mason NT, Joshi VB, Adashek JJ, Kim Y, Shah SS, Schneider AM, Chadha J, Jim HSL, Byrne MM, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023 Jun.6(3):331-338. Pubmedid: 36797084.
      • Brouwer OR, Albersen M, Parnham A, Protzel C, Pettaway CA, Ayres B, Antunes-Lopes T, Barreto L, Campi R, Crook J, Fernández-Pello S, Greco I, van der Heijden MS, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Garcia-Perdomo HA, Rumble RB, Sachdeva A, Sakalis VI, Zapala Ł, Sánchez Martínez DF, Spiess PE, Tagawa ST. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol. 2023 Jun.83(6):548-560. Pubmedid: 36906413.
      • Prakash G, Arora A, Bandini M, Basile G, Pal M, Griffiths G, Cornes R, Zhu Y, Rodriguez A, Alberson M, Necchi A, Master V, Pettaway CA, Spiess PE. Variations in Penile Cancer Management: Results From the Global Society of Rare Genitourinary Tumors Survey. Clin Genitourin Cancer. 2023 Jun.21(3):376-382. Pubmedid: 37037737.
      • McAlpine K, Clark R, Spiess PE, Necchi A, Gage K, Hamilton RJ. The Importance of Repeat Imaging Prior to Treatment Decision-making in Testicular Cancer: Commentary From the Inaugural Global Society of Rare Genitourinary Tumors Summit. Clin Genitourin Cancer. 2023 Jun.21(3):418.e1-418.e6. Pubmedid: 36624008.
      • Nguyen OT, Mason A, Charles D, Sprow O, Naso C, Turner K, Nahleh OA, Khanna N, Hong YR, Tabriz AA, Spiess P, Bottiglieri S. Patient and caregiver experience with telepharmacy in cancer care to support beginning systemic therapy: A qualitative study. J Oncol Pharm Pract. 2023 Jun. Pubmedid: 37312504.
      • Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):452. Pubmedid: 37217696.
      • Grass GD, Ercan D, Obermayer AN, Shaw T, Stewart PA, Chahoud J, Dhillon J, Lopez A, Johnstone PAS, Rogatto SR, Spiess PE, Eschrich SA. An Assessment of the Penile Squamous Cell Carcinoma Surfaceome for Biomarker and Therapeutic Target Discovery. Cancers (Basel). 2023 Jul.15(14). Pubmedid: 37509297. Pmcid: PMC10377392.
      • Parza K, Mustasam A, Ionescu F, Paravathaneni M, Sandstrom R, Safa H, Grass GD, Johnstone PA, Eschrich SA, Chadha J, Zacharias N, Pettaway CA, Spiess PE, Chahoud J. The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma-A Systematic Review. Cancers (Basel). 2023 Jul.15(14). Pubmedid: 37509374. Pmcid: PMC10378259.
      • Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):406-419. Pubmedid: 36977797.
      • Hacking SM, Pavlick D, Wang Y, Carneiro BA, Mullally M, Lu S, Canepa M, Bratslavsky G, Jacob J, Necchi A, Spiess PE, Wang L, Yakirevich E, Ross J. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy. Oncologist. 2023 Jul.28(7):e508-e519. Pubmedid: 36917021. Pmcid: PMC10322144.
      • Rose KM, Burke LR, Spiess PE. An Exercise Prescription To Improve Posture, Minimize Injury, and Improve Career Longevity in Surgeons. Eur Urol Focus. 2023 Jul.9(4):592-595. Pubmedid: 36804719.
      • Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023 Jul. Pubmedid: 37442673.
      • Patel KB, Gonzalez BD, Turner K, Alishahi Tabriz A, Rollison DE, Robinson E, Naso C, Wang X, Spiess PE. Estimated Carbon Emissions Savings With Shifts From In-Person Visits to Telemedicine for Patients With Cancer. JAMA Netw Open. 2023 Jan.6(1):e2253788. Pubmedid: 36719682. Pmcid: PMC9890284.
      • Spiess PE. Selection of best videos of the year for 2022. Int Braz J Urol. 2023 Jan.49(1):6-7. Pubmedid: 36512451. Pmcid: PMC9881812.
      • Patel KB, Turner K, Alishahi Tabriz A, Gonzalez BD, Oswald LB, Nguyen OT, Hong YR, Jim HSL, Nichols AC, Wang X, Robinson E, Naso C, Spiess PE. Estimated Indirect Cost Savings of Using Telehealth Among Nonelderly Patients With Cancer. JAMA Netw Open. 2023 Jan.6(1):e2250211. Pubmedid: 36626174. Pmcid: PMC9856804.
      • Yu A, Chahoud J, Necchi A, Spiess PE. The Evolving Landscape of Viral, Immune, and Molecular Biomarkers in Penile Cancer. Urol Clin North Am. 2023 Feb.50(1):145-150. Pubmedid: 36424078.
      • Padua TC, Marandino L, Raggi D, Hallanger-Johnson J, Kutikov A, Spiess PE, Necchi A. A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors. Clin Genitourin Cancer. 2023 Feb.21(1):1-7. Pubmedid: 36376169.
      • Diaz KA, Spiess PE, García-Perdomo HA. Humanization in oncology care: A necessary change. Urol Oncol. 2023 Feb.41(2):58-61. Pubmedid: 36509668.
      • Yan R, Ma H, Jiang L, Guo S, Shi Y, Sheng X, Zhang Y, Spiess PE, Liu T, Xue T, Chen X, Li Z, An X, Yao K, Zhou F, Han H. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer. BJU Int. 2023 Feb.131(2):198-207. Pubmedid: 35704436.
      • Necchi A, Spiess PE, Costa de Padua T, Li R, Grivas P, Huang RSP, Lin DI, Danziger N, Ross JS, Jacob JM, Sager RA, Basnet A, Li G, Graf RP, Pavlick DC, Bratslavsky G. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. JAMA Netw Open. 2023 Dec.6(12):e2348002. Pubmedid: 38150257. Pmcid: PMC10753400.
      • Ortiz-Guerra RA, Jaime-Casas S, Martinez-Cannon BA, Ariza-Avila JC, González-Morales AP, Bardan-Duarte A, Remolina-Bonilla YA, Spiess PE, Bourlon MT. Overview and characterization of penile cancer content across social media platforms. Front Oncol. 2023 Dec.13:1301973. Pubmedid: 38169747. Pmcid: PMC10758611.
      • El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst. 2023 Dec.115(12):1605-1615. Pubmedid: 37563779.
      • Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610. Eur Urol Oncol. 2023 Dec.6(6):638-639. Pubmedid: 37268448.
      • Ghelani GH, Zerdan MB, Jacob J, Spiess PE, Li R, Necchi A, Grivas P, Kamat A, Danziger N, Lin D, Huang R, Decker B, Sokol ES, Cheng L, Pavlick D, Ross JS, Bratslavsky G, Basnet A. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 Dec.41(12):486.e15-486.e23. Pubmedid: 37821306.
      • Greco I, Fernandez-Pello S, Sakalis VI, Barreto L, Albersen M, Ayres B, Antunes Lopes T, Campi R, Crook J, García Perdomo HA, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Parnham AS, Pettaway CA, Protzel C, Rumble RB, Sachdeva A, Sanchez Martinez DF, Zapala Ł, Tagawa ST, Spiess PE, Brouwer OR. Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma. Eur Urol Focus. 2023 Dec. Pubmedid: 38071107.
      • Esdaille AR, Karam JA, Master VA, Spiess PE, Raman JD, Sharma P, Shapiro DD, Das A, Sexton WJ, Zemp L, Patil D, Allen GO, Matin SF, Wood CG, Jason Abel E. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 Dec.182:168-174. Pubmedid: 37690543.
      • May M, Lebentrau S, Watkin N, Albersen M, Protzel C, Chahoud J, Brouwer OR, Pettaway CA, Pagliaro LC, Necchi A, Hakenberg OW, Ayres B, Spiess PE. [Initial presentation of the Pentafecta score as a quality instrument for outcome evaluation of primary surgical treatment in patients with penile cancer]. Aktuelle Urol. 2023 Aug.54(4):292-298. Pubmedid: 37339668.
      • Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Uro. Eur Urol. 2023 Aug.84(2):e55-e56. Pubmedid: 37149462.
      • D'Andrea D, Shariat SF, Soria F, DI Trapani E, Mertens LS, VAN Rhijn BW, Dinney CP, Black PC, Spiess PE, Carrion DM, Pradere B, Tonin E, Pichler R, Filippot R, Mari A, Moschini M. Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. Minerva Urol Nephrol. 2023 Aug.75(4):452-459. Pubmedid: 37314813.
      • Candelario NC, Molina E, Bourlon MT, Kim SP, Kessler ER, Spiess PE, Flaig TW. Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database. Urol Oncol. 2023 Aug.41(8):359.e15-359.e23. Pubmedid: 37344326.
      • Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci. 2023 Apr.50:43-46. Pubmedid: 36861106. Pmcid: PMC9969293.
      • May M, Lebentrau S, Ayres B, Albersen M, Protzel C, Chahoud J, Brouwer OR, Pettaway CA, Pagliaro LC, Necchi A, Watkin N, Hakenberg OW, Spiess PE. The Goal of Achieving High-Quality Surgical First-Line Therapy in Patients with Penile Cancer Is Important; However, Some Collective Efforts Are Still Required in Order to Reach It. Comment on Brassetti et al. Combined Reporting of Surgical Quality and Ca. Curr Oncol. 2023 Apr.30(4):4269-4274. Pubmedid: 37185438. Pmcid: PMC10136864.
      • Rose KM, Narang G, Rosen G, Labatte C, Dumitrascu C, Campagna J, Yu A, Manley BJ, Spiess PE, Li R, Adibi M, Murray KS, Sexton WJ, Humphreys MR. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2023 Apr.131(4):471-476. Pubmedid: 36285629.
      • Chakiryan NH, Kim Y, Berglund A, Chang A, Kimmel GJ, Hajiran A, Nguyen J, Moran-Segura C, Saeed-Vafa D, Katende EN, Lopez-Blanco N, Chahoud J, Rappold P, Spiess PE, Fournier M, Jeong D, Wang L, Teer JK, Dhillon J, Kuo F, Hakimi AA, Altrock PM, Mulé JJ, Manley BJ. Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma. J Immunother Cancer. 2023 Apr.11(4). Pubmedid: 37185232. Pmcid: PMC10151991.
      • Necchi A, Joshi M, Bangs R, Makaroff L, Grivas P, Kamat AM, Kassouf W, Raggi D, Marandino L, Krupski T, Flaig TW, Spiess PE. Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clin Genitourin Cancer. 2023 Apr.21(2):301-308. Pubmedid: 36344399.
      • García-Perdomo HA, Sánchez AL, Spiess PE. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review. Urol Oncol. 2022 Sep.40(9):409.e1-409.e8. Pubmedid: 35232680.
      • Chadha J, Chahoud J, Spiess PE. An update on treatment of penile cancer. Ther Adv Med Oncol. 2022 Sep.14. Pubmedid: 36172172. Pmcid: PMC9511530.
      • Youssef I, Hoogland AI, Chahoud J, Spiess PE, Jim H, Johnstone PAS. Patient reported outcomes in advanced penile cancer. Urol Oncol. 2022 Sep.40(9):412.e9-412.e13. Pubmedid: 35662500.
      • Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
      • Patel A, Naghavi AO, Johnstone PA, Spiess PE, Grass GD. Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer. Asian J Urol. 2022 Oct.9(4):389-406. Pubmedid: 36381600. Pmcid: PMC9643293.
      • Huang J, Chan SC, Tin MS, Liu X, Lok VT, Ngai CH, Zhang L, Lucero-Prisno DE, Xu W, Zheng ZJ, Chiu PK, Ng AC, Enikeev D, Nicol D, Spiess PE, Laguna P, Teoh JY, Wong MCS. Worldwide Distribution, Risk Factors, and Temporal Trends of Testicular Cancer Incidence and Mortality: A Global Analysis. Eur Urol Oncol. 2022 Oct.5(5):566-576. Pubmedid: 35863988.
      • Spiess PE, Necchi A. Advancing the field of rare genitourinary tumors: Challenges and opportunities. Asian J Urol. 2022 Oct.9(4):347-348. Pubmedid: 36381594. Pmcid: PMC9643284.
      • Lonati C, Simeone C, Suardi N, Spiess PE, Necchi A, Moschini M. Genitourinary manifestations of Lynch syndrome in the urological practice. Asian J Urol. 2022 Oct.9(4):443-450. Pubmedid: 36381590. Pmcid: PMC9643301.
      • Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
      • DePalo DK, Elleson KM, Carr MJ, Spiess PE, Zager JS. Genitourinary melanoma: An overview for the clinician. Asian J Urol. 2022 Oct.9(4):407-422. Pubmedid: 36381597. Pmcid: PMC9643129.
      • Soliman C, Thomas BC, Santaguida P, Lawrentschuk N, Mertens E, Giannarini G, Wuethrich PY, Wu M, Khan MS, Nair R, Thurairaja R, Challacombe B, Dasgupta P, Malde S, Corcoran NM, Spiess PE, Dundee P, Furrer MA. Active involvement of nursing staff in reporting and grading complication-intervention events-Protocol and results of the CAMUS Pilot Nurse Delphi Study. BJUI Compass. 2022 Nov.3(6):466-483. Pubmedid: 36267199. Pmcid: PMC9579890.
      • Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Zargar-Shoshtari K, Spiess PE, van Rhijn BWG, Black PC, Mertens LS. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol. 2022 Nov.40(11):2707-2715. Pubmedid: 36169695.
      • Liu JKC, Kang R, Bilenkin A, Prorok R, Whiting J, Patel KB, Beer-Furlan A, Naso C, Rogers A, Castro XB, Peguero E, Mokhtari S, Tran N, Etame A, Pina Y, Spiess PE, Forsyth P, Vogelbaum MA. Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department. J Neurooncol. 2022 Nov.160(2):517-525. Pubmedid: 36367630. Pmcid: PMC9651094.
      • Diaz KA, Spiess PE, García-Perdomo HA. Patient-Reported Outcomes in Penile Cancer Patients: Quality of Life, Sexual and Urinary Function. What do we Know?. Urology. 2022 Nov.169:1-5. Pubmedid: 36037936.
      • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
      • Hajiran A, Bracco T, Zemp L, Spiess PE. Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma. Urol Oncol. 2022 May.40(5):173-178. Pubmedid: 32690436.
      • Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
      • Korkes F, Spiess PE, Garcia-Perdomo HA, Necchi A. Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review. Int Braz J Urol. 2022 May.48(3):397-405. Pubmedid: 34156188. Pmcid: PMC9060175.
      • Pettaway CA, Spiess PE. Multimodality treatment of penile cancer: Part 1. Urol Oncol. 2022 May.40(5):171-172. Pubmedid: 35410775.
      • Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffeille V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. Eur Urol Focus. 2022 Mar.8(2):491-497. Pubmedid: 33773965.
      • Yuan Z, Yang GQ, Ahmed KA, Torres-Roca JF, Spiess PE, Johnstone PA. Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?. Urol Oncol. 2022 Jun.40(6):223-228. Pubmedid: 32482510.
      • Sood A, Rudzinski JK, Spiess PE, Pettaway CA. The Acute Complications After Surgery for Penile Carcinoma and Strategies for Their Management: A Systematic Review of the Literature. Semin Oncol Nurs. 2022 Jun.38(3):151285. Pubmedid: 35597731.
      • Hugar LA, Filippou P, Thirlwell S, Spiess PE, Wulff-Burchfield EM. Is There a Role for Palliative Services and Supportive Care in Managing Advanced Penile Cancer?. Semin Oncol Nurs. 2022 Jun.38(3):151288. Pubmedid: 35610159.
      • Spiess PE, Necchi A. Introduction. Semin Oncol Nurs. 2022 Jun.38(3):151281. Pubmedid: 35577639.
      • Sakalis VI, Campi R, Barreto L, Perdomo HG, Greco I, Zapala Ł, Kailavasan M, Antunes-Lopes T, Marcus JD, Manzie K, Osborne J, Ayres B, Moonen LMF, Necchi A, Crook J, Oliveira P, Pagliaro LC, Protzel C, Parnham AS, Albersen M, Pettaway CA, Spiess PE, Tagawa ST, Rumble RB, Brouwer OR. What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. Eur Urol Open Sci. 2022 Jun.40:58-94. Pubmedid: 35540709. Pmcid: PMC9079254.
      • Bourlon MT, Verduzco-Aguirre H, Molina E, Meyer E, Kessler E, Kim SP, Spiess PE, Flaig T. Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis. Front Oncol. 2022 Jun.12:926692. Pubmedid: 35847850. Pmcid: PMC9277543.
      • Arora A, Rodriguez A, Necchi A, Albersen M, Zhu Y, Spiess PE, Prakash G. Global Implications in Caring for Penile Cancer: Similarities and Divergences. Semin Oncol Nurs. 2022 Jun.38(3):151283. Pubmedid: 35643731.
      • Pettaway CA, Spiess PE. Multimodality treatment of penile cancer: Part 2. Urol Oncol. 2022 Jun.40(6):207-208. Pubmedid: 35469703.
      • Vinueza-Obando D, Spiess PE, García-Perdomo HA. Pembrolizumab as a promising intervention for advanced penile cancer. Int Braz J Urol. 2022 Jul.48(4):719-721. Pubmedid: 35373954. Pmcid: PMC9306374.
      • Spiess PE. Selection of best videos of the year for 2021. Int Braz J Urol. 2022 Jan.48(1):6-7. Pubmedid: 34735080. Pmcid: PMC8691245.
      • D'Andrea D, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carrión DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 Jan.207(1):70-76. Pubmedid: 34445891.
      • Turner K, Bobonis Babilonia M, Naso C, Nguyen O, Gonzalez BD, Oswald LB, Robinson E, Elston Lafata J, Ferguson RJ, Alishahi Tabriz A, Patel K, Hallanger-Johnson J, Aldawoodi N, Hong YR, Jim HSL, Speiss PE. Health Care Providers' and Professionals' Experiences With Telehealth Oncology Implementation During the COVID-19 Pandemic: A Qualitative Study. J Med Internet Res. 2022 Jan.24(1):e29635. Pubmedid: 34907900. Pmcid: PMC8772877.
      • Lonati C, Moschini M, Simeone C, Spiess PE, Necchi A. Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma. Curr Opin Urol. 2022 Jan.32(1):40-47. Pubmedid: 34608026.
      • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
      • Lonati C, Necchi A, Gómez Rivas J, Afferi L, Laukhtina E, Martini A, Ventimiglia E, Colombo R, Gandaglia G, Salonia A, Briganti A, Montorsi F, Mattei A, Simeone C, Carlo MI, Shariat SF, Spiess PE, Moschini M. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. Eur Urol Oncol. 2022 Feb.5(1):30-41. Pubmedid: 34896051.
      • Johnstone PAS, Spiess PE, Sedor G, Grass GD, Yamoah K, Scott JG, Torres-Roca JF. Changing Radiotherapy Paradigms in Penile Cancer. Eur Urol Open Sci. 2022 Feb.36:47-48. Pubmedid: 35028598. Pmcid: PMC8739469.
      • Diaz KA, Spiess PE, Necchi A, Li R, Bandini M, García-Perdomo HA. How to get involved in clinical research: helpful tips. Can J Urol. 2022 Feb.29(1):11024-11026. Pubmedid: 35150226.
      • Crook J, Black PC, Spiess PE, Pettaway C. The first International Penile Advanced Cancer Trial (InPACT) opens in Canada! Why additional centers are needed. Can Urol Assoc J. 2022 Feb.16(2):70-71. Pubmedid: 35133267. Pmcid: PMC8932418.
      • Giannone G, Giuliano AR, Bandini M, Marandino L, Raggi D, Earle W, Ayres B, Pettaway CA, McNeish IA, Spiess PE, Necchi A. HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. Cancer Treat Rev. 2022 Dec.111:102467. Pubmedid: 36265336.
      • Ortíz Restrepo A, Ross JS, Spiess PE, Necchi A, Li R, García-Perdomo HA. Emerging targets in upper tract urothelial carcinomas: the TERT gene. Can J Urol. 2022 Dec.29(6):11378-11383. Pubmedid: 36495580.
      • Peak T, Zemp L, Spiess P. Will Dynamic Sentinel Lymph Node Biopsy Surpass Inguinal Lymph Node Dissection in High-risk Node-negative Penile Cancer?. Eur Urol Oncol. 2022 Dec.5(6):712-713. Pubmedid: 36336613.
      • Necchi A, Spiess PE, Bandini M, Basile G, Grivas P, Bratslavsky G, Jacob J, Danziger N, Lin D, Decker B, Sokol ES, Huang RSP, Kulkarni SB, Ross JS. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. Oncologist. 2022 Dec.27(12):1016-1024. Pubmedid: 35881043.
      • Rishi A, Saini AS, Spiess PE, Yu A, Fernandez DC, Johnstone PAS, Naghavi AO. Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer. Brachytherapy. 2022 Aug.21(6):839-847. Pubmedid: 35915039.
      • Joshi VB, Spiess PE, Necchi A, Pettaway CA, Chahoud J. Immune-based therapies in penile cancer. Nat Rev Urol. 2022 Aug.19(8):457-474. Pubmedid: 35851333.
      • Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Ne. 2022 Aug.20(8):866-878. Pubmedid: 35948037.
      • Martini A, Fallara G, Pellegrino AA, Nocera L, Larcher A, Raggi D, Campi R, Ploussard G, Malavaud B, Montorsi F, Pal SK, Spiess PE, Choueiri TK, Necchi A, Capitanio U. Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. Urol Oncol. 2022 Aug.40(8):384.e9-384.e14. Pubmedid: 35667983.
      • Zhang Y, Kumar P, Adashek JJ, Skelton WP, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells. 2022 Aug.11(16). Pubmedid: 36010582. Pmcid: PMC9406439.
      • Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss. Clin Genitourin Cancer. 2022 Apr.20(2):e158-e165. Pubmedid: 34974985.
      • Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. J Natl Cancer Inst. 2022 Apr.114(4):571-578. Pubmedid: 34893865. Pmcid: PMC9002283.
      • Bandini M, Ahmed M, Basile G, Watkin N, Master V, Zhu Y, Prakash G, Rodriguez A, Ssebakumba MK, Leni R, Cirulli GO, Ayres B, Compitello R, Pederzoli F, Joshi PM, Kulkarni SB, Montorsi F, Sonpavde G, Necchi A, Spiess PE. Author Correction: A global approach to improving penile cancer care. Nat Rev Urol. 2022 Apr.19(4):253. Pubmedid: 35043020. Pmcid: PMC9119274.
      • Johnstone PAS, de Vries HM, Chipollini J, Grass GD, Boyd F, Korkes F, Albersen M, Roussel E, Zhu Y, Ye DW, Master V, Le TL, Muneer A, Brouwer OR, Spiess PE. Impact of radiation therapy on perineal urethrostomy for penile cancer. Clin Transl Radiat Oncol. 2021 Sep.30:84-87. Pubmedid: 34430718. Pmcid: PMC8367760.
      • Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. medRxiv. 2021 Sep. Pubmedid: 34611665. Pmcid: PMC8491856.
      • Zekan DS, Dahman A, Hajiran AJ, Luchey AM, Chahoud J, Spiess PE. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol. 2021 Sep.47(5):943-956. Pubmedid: 33650835. Pmcid: PMC8321459.
      • Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. J Urol. 2021 Oct.206(4):960-969. Pubmedid: 34032492.
      • Bandini M, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres BA, Hakenberg OW, Heidenreich A, Salvioni R, Catanzaro M, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. Eur Urol Oncol. 2021 Oct.4(5):802-810. Pubmedid: 33199252.
      • Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. Reply by Authors. J Urol. 2021 Oct.206(4):969. Pubmedid: 34379451.
      • Basile G, Pederzoli F, Bandini M, Raggi D, Gallina A, Salonia A, Briganti A, Montorsi F, Spiess PE, Necchi A. Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. Urol Oncol. 2021 Oct.39(10):631-641. Pubmedid: 33766463.
      • Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffeille V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol. 2021 Oct.80(4):507-515. Pubmedid: 34023164.
      • Thomas A, do Canto Alvim LM, Rainho CA, Juengel E, Blaheta RA, Spiess PE, Rogatto SR, Tsaur I. Systemic treatment of penile squamous cell carcinoma-hurdles and hopes of preclinical models and clinical regimens: a narrative review. Transl Androl Urol. 2021 Oct.10(10):4085-4098. Pubmedid: 34804850. Pmcid: PMC8575571.
      • Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand D, Black PC. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. Eur Urol Focus. 2021 Nov.7(6):1347-1354. Pubmedid: 32771446.
      • Khalil MI, Kamel MH, Dhillon J, Master V, Davis R, Hajiran AJ, Spiess PE. What you need to know: updates in penile cancer staging. World J Urol. 2021 May.39(5):1413-1419. Pubmedid: 32572556.
      • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
      • Roussel E, Peeters E, Vanthoor J, Bozzini G, Muneer A, Ayres B, Sri D, Watkin N, Bhattar R, Parnham A, Sangar V, Lau M, Joice G, Bivalacqua TJ, Chipollini J, Spiess PE, Hatzichristodoulou G, de Vries L, Brouwer O, Albersen M. Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma?. BJU Int. 2021 May.127(5):606-613. Pubmedid: 33180969.
      • Saidian A, Ceballos B, Necchi A, Baumgarten AS, Spiess PE. Salvage therapy for localized recurrences of penile cancer. Curr Opin Urol. 2021 May.31(3):214-219. Pubmedid: 33742976.
      • Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May.94:107481. Pubmedid: 33636562. Pmcid: PMC8205103.
      • D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, Shariat SF. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 May.127(5):528-537. Pubmedid: 32981193. Pmcid: PMC8246716.
      • Abreu D, Carvalhal G, Gueglio G, Tobia I, Garcia P, Zuñiga A, Meza L, Bengió R, Scorticati C, Castillejos R, Rodriguez F, Autran AM, Gonzales C, Gadu J, Nolazco A, Ameri C, Zampolli H, Langenhin R, Muguruza D, Machado MT, Mingote P, Yandian J, Clavijo J, Nogueira L, Clark O, Secin F, Rovegno A, Vilas A, Barrios E, Decia R, Guimarães G, Glina S, Pal SK, Rodriguez O, Palou J, Spiess P, Lara PN, Linehan WM, Pastore AL, Zequi SC. Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. JCO Glob Oncol. 2021 May.7:671-685. Pubmedid: 33974442. Pmcid: PMC8162501.
      • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
      • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
      • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
      • Chahoud J, Kohli M, Spiess PE. Management of Advanced Penile Cancer. Mayo Clin Proc. 2021 Mar.96(3):720-732. Pubmedid: 33308870.
      • Chakiryan NH, Dahmen A, Cucchiara V, Briganti A, Montorsi F, Salonia A, Spiess PE, Necchi A. Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review. J Urol. 2021 Jun.205(6):1569-1576. Pubmedid: 33617328.
      • Marilin N, Master VA, Pettaway CA, Spiess PE. Current practice patterns of society of urologic oncology members in performing inguinal lymph node staging/therapy for penile cancer: A survey study. Urol Oncol. 2021 Jul.39(7):439.e9-439.e15. Pubmedid: 33775532.
      • Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2021 Jul.39(7):2409-2415. Pubmedid: 32936333. Pmcid: PMC8101019.
      • Kakies C, Louise Dräger D, Spiess P, Hakenberg OW, Protzel C. [Conventional grading vs. molecular grading : Decision aids for clinical routine]. Urologe A. 2021 Jul.60(7):886-894. Pubmedid: 34184100.
      • Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Daneshmand S, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Shariat SF, Gontero P. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021 Jul.128(1):79-87. Pubmedid: 33152179.
      • Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
      • Johnstone PAS, Canter D, Spiess PE. Reply to Vedang Murthy, Abhilash Gavarraju, and Rahul Krishnatry's Letter to the Editor re: Peter A.S. Johnstone, David Boulware, Rosa Djajadiningrat, et al. Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Ext. Eur Urol Focus. 2021 Jan.7(1):226. Pubmedid: 31000494.
      • Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 Jan.39(1):72.e1-72.e5. Pubmedid: 33036902.
      • Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran ATH, Van Rompuy AS, Spiess PE, Albersen M. Penile cancer. Nat Rev Dis Primers. 2021 Feb.7(1):11. Pubmedid: 33574340.
      • Bandini M, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres B, Hakenberg OW, Heidenreich A, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. Eur Urol Oncol. 2021 Feb.4(1):121-123. Pubmedid: 32943378.
      • Necchi A, Pederzoli F, Bandini M, Spiess PE. Revolutionizing care for rare genitourinary tumours. Nat Rev Urol. 2021 Feb.18(2):69-70. Pubmedid: 33235393.
      • Adashek JJ, Zhang Y, Skelton WP, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Front Oncol. 2021 Feb.10:627025. Pubmedid: 33643921. Pmcid: PMC7902859.
      • Necchi A, Cucchiara V, Grivas P, Bratslavsky G, Jacob J, Spiess PE, Sokol ES, Killian JK, Lin D, Ramkissoon S, Huang RSP, Madison RW, Venstrom JM, Schrock AB, Danziger N, Decker B, Gjoerup O, Graf RP, Oxnard GR, Tukachinsky H, Ross JS. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer. 2021 Dec.127(24):4557-4564. Pubmedid: 34379803.
      • Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. Urol Oncol. 2021 Dec.39(12):838.e7-838.e13. Pubmedid: 34602362.
      • D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec.39(12):4345-4354. Pubmedid: 34370078. Pmcid: PMC8602146.
      • de Vries HM, Chipollini J, Slongo J, Boyd F, Korkes F, Albersen M, Roussel E, Zhu Y, Ye DW, Master V, Le TL, Johnstone PA, Muneer A, Brouwer OR, Spiess PE. Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience. Urol Oncol. 2021 Aug.39(8):500.e9-500.e13. Pubmedid: 34134926.
      • Dahmen A, Spiess PE. Editorial Comment. J Urol. 2021 Aug.206(2):362-363. Pubmedid: 33955772.
      • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
      • Jain RK, Ross JS, Necchi A, Spiess PE. Should Upper-tract Urothelial Carcinoma and Bladder Carcinoma Be Treated the Same or Different?. Eur Urol Oncol. 2021 Apr.4(2):180-181. Pubmedid: 33602655.
      • Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
      • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
      • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
      • Ahmed ME, Falasiri S, Hajiran A, Chahoud J, Spiess PE. The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy. J Clin Med. 2020 Oct.9(10). Pubmedid: 33080912. Pmcid: PMC7603091.
      • Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 Oct.17(10):555-570. Pubmedid: 32812000.
      • Ahmed ME, Khalil MI, Kamel MH, Karnes RJ, Spiess PE. Progress on Management of Penile Cancer in 2020. CURR TREAT OPTION ON. 2020 Nov.22(1):4. Pubmedid: 33230601.
      • Bandini M, Spiess PE, Pederzoli F, Marandino L, Brouwer OR, Albersen M, Roussel E, de Vries HM, Chipollini J, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Ahmed ME, Karnes JR, Briganti A, Salvioni R, Montorsi F, Azizi M, Necchi A. A risk calculator predicting recurrence in lymph node metastatic penile cancer. BJU Int. 2020 Nov.126(5):577-585. Pubmedid: 32662205.
      • Korkes F, Rodrigues AFS, Baccaglini W, Cunha FTS, Slongo J, Spiess P, Glina S. Penile cancer trends and economic burden in the Brazilian public health system. Einstein (Sao Paulo). 2020 Nov.18:eAO5577. Pubmedid: 33174969. Pmcid: PMC7607917.
      • Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
      • Wang B, Gu W, Wan F, Wei Y, Xiao W, Lu X, Zhang G, Zhou J, Wang Q, Ding X, Azizi M, Spiess PE, Ye D, Zhu Y. Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. J Urol. 2020 Mar.203(3):562-569. Pubmedid: 31596650.
      • Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Mar.18(3):329-354. Pubmedid: 32135513.
      • Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. J Urol. 2020 Jun.203(6):1147-1155. Pubmedid: 31928407.
      • Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Reply by Authors. J Urol. 2020 Jun.203(6):1155. Pubmedid: 32176595.
      • Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2020 Jun.203(6):1101-1108. Pubmedid: 31898919.
      • Ghahhari J, Marchioni M, Spiess PE, Chipollini JJ, Nyirády P, Varga J, Ditonno P, Boccasile S, Primiceri G, De Nunzio C, Tema G, Tubaro A, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Puliatti S, Micali S, Álvarez-Maestro M, Quesada Olarte J, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Sosnowski R, Schips L, Cindolo L. Radical penectomy, a compromise for life: results from the PECAD study. Transl Androl Urol. 2020 Jun.9(3):1306-1313. Pubmedid: 32676414. Pmcid: PMC7354339.
      • Bandini M, Albersen M, Chipollini J, Pederzoli F, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M, Haidl F, Mazzone E, Marandino L, Briganti A, Montorsi F, Azizi M, Spiess PE, Necchi A. Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. BJU Int. 2020 Jun.125(6):867-875. Pubmedid: 32175663.
      • Spiess PE, Greene J, Keenan RJ, Paculdo D, Letson GD, Peabody JW. Meeting the challenge of the 2019 novel coronavirus disease in patients with cancer. Cancer. 2020 Jul.126(14):3174-3175. Pubmedid: 32324273. Pmcid: PMC7264676.
      • D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 Jul.38(7):639.e1-639.e9. Pubmedid: 32057595.
      • Chipollini J, Wright JR, Nwanosike H, Kepler CY, Batai K, Lee BR, Spiess PE, Stewart DB, Lamendella R. Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study. Urol Oncol. 2020 Jul.38(7):615-621. Pubmedid: 32414567.
      • D'Andrea D, Foerster B, Matin SF, Ku JH, Muilwijk T, Monteiro LL, Liao R, Petros FG, Spiess PE, Bivalacqua TJ, Hendricksen K, van Rhijn BWG, Shabsigh A, Briganti A, Joniau S, Kassouf W, Pierorazio PM, Margulis V, Necchi A, Shariat SF. Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. Eur Urol Open Sci. 2020 Jul.19:16-19. Pubmedid: 34337449. Pmcid: PMC8317786.
      • Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 Jan.6(1):104-111. Pubmedid: 30206003. Pmcid: PMC7771285.
      • Chipollini J, Azizi M, Lo Vullo S, Mariani L, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg O, Heidenreich A, Raggi D, Catanzaro M, Ornellas P, Salvioni R, Necchi A, Spiess PE. Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU Int. 2020 Jan.125(1):82-88. Pubmedid: 31356716.
      • Spiess PE. Selection of best videos of the year for 2020. Int Braz J Urol. 2020 Jan.47(1):6-7. Pubmedid: 33047909. Pmcid: PMC7712680.
      • Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020 Jan.38(1):3.e17-3.e27. Pubmedid: 31676278.
      • Spiess PE. Best videos of the year for 2019. Int Braz J Urol. 2020 Jan.46(1):3-4. Pubmedid: 31851452. Pmcid: PMC6968903.
      • Reyes ME, Borges H, Adjao MS, Vijayakumar N, Spiess PE, Schabath MB. Novel Prognostic Models for Patients With Penile Carcinoma. Cancer Control. 2020 Jan.27(1). Pubmedid: 32397742. Pmcid: PMC7223867.
      • Peyton CC, Hajiran A, Morgan K, Azizi M, Tang D, Chipollini J, Gilbert SM, Poch M, Sexton WJ, Spiess PE. Urinary leak following partial nephrectomy: a contemporary review of 975 cases. Can J Urol. 2020 Feb.27(1):10118-10124. Pubmedid: 32065869.
      • Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE, Briganti A, Bandini M, Goffin K, Bouchelouche K, van Werkhoven E, Shariat SF, Xylinas E, Azawi NH, Ku JH, Foerster B, van Rhijn BWG, Vegt E, Hendricksen K. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2020 Feb.3(1):73-79. Pubmedid: 31591037.
      • Dreyfuss LD, Master VA, Raman JD, Spiess PE, Wells SA, Merrill SB, Peyton CC, Sankar D, Sohl B, Patil D, Shapiro DD, Allen GO, Abel EJ. Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma. Urology. 2020 Dec.146:152-157. Pubmedid: 32781079.
      • Aydin AM, Chakiryan NH, Spiess PE. Will Dynamic Sentinel Lymph Node Biopsy Become the New International Standard for Evaluating High-risk Penile Cancer in Patients with Clinically Negative Lymph Nodes?. Eur Urol. 2020 Dec.78(6):873-874. Pubmedid: 33023773.
      • Chahoud J, Skelton WP, Spiess PE, Walko C, Dhillon J, Gage KL, Johnstone PAS, Jain RK. Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab. Front Oncol. 2020 Dec.10:615298. Pubmedid: 33425770. Pmcid: PMC7793656.
      • Necchi A, Gallina A, Dyrskjøt L, Roupret M, Kamat AM, Spiess PE, Grivas P, Gibb EA, Briganti A, Montorsi F. Converging Roads to Early Bladder Cancer. Eur Urol. 2020 Aug.78(2):127-130. Pubmedid: 32197887.
      • Kumar NB, Pow-Sang J, Spiess P, Dickinson S, Schell MJ. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020 Apr.11(14):1218-1234. Pubmedid: 32292572. Pmcid: PMC7147089.
      • Aydin AM, Cheriyan S, Spiess PE. Treating advanced penile cancer: where do we stand in 2019?. Curr Opin Support Palliat Care. 2019 Sep.13(3):249-254. Pubmedid: 31082941.
      • Necchi A, Ross JS, Spiess PE. Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors. J Clin Oncol. 2019 Sep.37(26):2314-2316. Pubmedid: 31361537.
      • Chipollini J, da Costa WH, Werneck da Cunha I, de Almeida E Paula F, Guilherme O Salles P, Azizi M, Spiess PE, Abreu D, Zequi SC. Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Ther Adv Urol. 2019 Oct.11. Pubmedid: 31662794. Pmcid: PMC6792277.
      • Yuan Z, Grass GD, Azizi M, Ahmed KA, Yoder GSJ, Welsh EA, Fulp WJ, Dhillon J, Torres-Roca JF, Giuliano AR, Spiess PE, Johnstone PA. Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy. Rep Pract Oncol Radiother. 2019 Nov.24(6):593-599. Pubmedid: 31719799. Pmcid: PMC6839006.
      • Chipollini J, Garcia-Castaneda J, Rosa AH, Cheriyan S, Azizi M, Spiess PE. Important surgical concepts and techniques in inguinal lymph node dissection. Curr Opin Urol. 2019 May.29(3):286-292. Pubmedid: 30730389.
      • Kamel MH, Khalil MI, Davis R, Spiess PE. Management of the Clinically Negative (cN0) Groin Penile Cancer Patient: A Review. Urology. 2019 May.131:5-13. Pubmedid: 31129195.
      • Khalil MI, Wan F, Eltahawy E, Davis R, Spiess PE, Bissada NK, Kamel MH. Survival Following Salvage Surgery after Failed Radiotherapy for Penile Cancer: A SEER-Based Study. Curr Urol. 2019 May.12(3):142-146. Pubmedid: 31316322. Pmcid: PMC6613318.
      • Azizi M, Chipollini J, Peyton CC, Cheriyan SK, Spiess PE. Current controversies and developments on the role of lymphadenectomy for penile cancer. Urol Oncol. 2019 Mar.37(3):201-208. Pubmedid: 30301700.
      • Slongo J, Jain RK, Spiess PE. Important caveats of KEYNOTE-045: relevance of these findings in the current and future therapeutic paradigm. Ann Transl Med. 2019 Mar.7(Suppl 1):S23. Pubmedid: 31032303. Pmcid: PMC6462609.
      • Albersen M, Spiess P. Editorial: penile cancer. Curr Opin Urol. 2019 Mar.29(2):143-144. Pubmedid: 30601185.
      • Park JY, Luu HN, Park HY, Lin HY, Radlein S, Di Pietro G, Yeo CD, Kim SJ, Kang N, Antwi S, Sexton WJ, Spiess PE, Dickinson S, Parker A. Telomere length in peripheral blood leukocytes and risk of renal cell carcinoma. Transl Cancer Res. 2019 Jul.8(Suppl 4):S397-S403. Pubmedid: 35117117. Pmcid: PMC8798989.
      • Li R, Spiess PE, Gilbert SM, Necchi A. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. 2019 Jul.76(1):4-6. Pubmedid: 30833139.
      • Adashek JJ, Necchi A, Spiess PE. Updates in the molecular epidemiology and systemic approaches to penile cancer. Urol Oncol. 2019 Jul.37(7):403-408. Pubmedid: 31053523.
      • Johnstone PAS, Spiess PE, Giuliano AR. New directions in penile cancer. Lancet Oncol. 2019 Jan.20(1):16-17. Pubmedid: 30573286.
      • Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan.37(1):165-172. Pubmedid: 29882105.
      • Azizi M, Tang DH, Verduzco D, Peyton CC, Chipollini J, Yuan Z, Schaible BJ, Zhou JM, Johnstone PA, Giuliano A, Dhillon J, Spiess PE. Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature. Clin Genitourin Cancer. 2019 Feb.17(1):e80-e91. Pubmedid: 30318447. Pmcid: PMC9339208.
      • Chipollini J, De la Rosa AH, Azizi M, Shayegan B, Zorn KC, Spiess PE. Patient presentation, differential diagnosis, and management of penile lesions. Can Urol Assoc J. 2019 Feb.13(2 Suppl 1):S2-S8. Pubmedid: 31237837. Pmcid: PMC6620174.
      • Zhu Y, Gu WJ, Xiao WJ, Wang BH, Azizi M, Spiess PE, Ye DW. Important Therapeutic Considerations in T1b Penile Cancer: Prognostic Significance and Adherence to Treatment Guidelines. Ann Surg Oncol. 2019 Feb.26(2):685-691. Pubmedid: 30565040.
      • Slongo J, Giuliano AR, Johnstone PA, Spiess PE. The relationship between HPV and penile cancer: Filling a knowledge gap in the general population. Can Urol Assoc J. 2019 Feb.13(2):38. Pubmedid: 30721126. Pmcid: PMC6363573.
      • Zhu Y, Spiess PE, Ye DW. ASO Author Reflections: T1b Penile Cancer: An Alarm to Improve Treatment. Ann Surg Oncol. 2019 Feb.26(2):692-693. Pubmedid: 30556119.
      • Spiess PE. Updates on the Management of Rare Genitourinary Malignancies: Where Do We Stand?. Eur Urol Focus. 2019 Feb.5(5):701. Pubmedid: 30772359.
      • Adashek JJ, Leonard A, Nealon SW, Krishnan A, Mosiello GC, Dhillon J, Spiess PE. Extramammary Paget's disease: what do we know and how do we treat?. Can J Urol. 2019 Dec.26(6):10012-10021. Pubmedid: 31860417.
      • Necchi A, Lo Vullo S, Mariani L, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M, Salvioni R, Chipollini J, Azizi M, Spiess PE. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urol Oncol. 2019 Aug.37(8):531.e7-531.e15. Pubmedid: 31053524.
      • Li R, Spiess PE, Gilbert SM, Necchi A. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Eur Urol. 2019 Aug.76(2):e34. Pubmedid: 31056228.
      • Hoffman MS, Spiess PE. Simulated management of urinary tract injury during robotic pelvic surgery utilizing the porcine model. J Robot Surg. 2019 Apr.13(2):289-292. Pubmedid: 30014233.
      • Azizi M, Cheriyan SK, Peyton CC, Foerster B, Shariat SF, Spiess PE. Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. CURR TREAT OPTION ON. 2019 Apr.20(5):40. Pubmedid: 30937554.
      • Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Ne. 2018 Sep.16(9):1041-1053. Pubmedid: 30181416.
      • Patel SY, Garcia Getting RE, Alford B, Hussein K, Schaible BJ, Boulware D, Lee JK, Gilbert SM, Powsang JM, Sexton WJ, Spiess PE, Poch MA. Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center. World J Surg. 2018 Sep.42(9):2701-2707. Pubmedid: 29750321. Pmcid: PMC7771278.
      • Di Pietro G, Luu HN, Spiess PE, Sexton W, Dickinson S, Parker A, Park JY. Biomarkers and new therapeutic targets in renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018 Sep.22(18):5874-5891. Pubmedid: 30280768.
      • Yuan Z, Naghavi AO, Tang D, Kim Y, Ahmed KA, Dhillon J, Giuliano AR, Spiess PE, Johnstone PA. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World J Urol. 2018 Sep.36(9):1431-1440. Pubmedid: 29589134. Pmcid: PMC7771321.
      • Chipollini J, Azizi M, Peyton CC, Tang DH, Dhillon J, Spiess PE. Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. J Kidney Cancer VHL. 2018 Oct.5(4):6-13. Pubmedid: 30386718. Pmcid: PMC6186848.
      • Johnstone PAS, Boulware D, Djajadiningrat R, Ottenhof S, Necchi A, Catanzaro M, Ye D, Zhu Y, Nicolai N, Horenblas S, Spiess PE. Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. Eur Urol Focus. 2018 Oct.5(5):737-741. Pubmedid: 30327282. Pmcid: PMC7771242.
      • Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer. 2018 Oct.16(5):e1003-e1013. Pubmedid: 29859736.
      • Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. Eur Urol. 2018 Oct.74(4):405-408. Pubmedid: 29685644.
      • Cindolo L, Spiess PE, Bada M, Chipollini JJ, Nyirády P, Chiodini P, Varga J, Ditonno P, Battaglia M, De Nunzio C, Tema G, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Micali S, Maestro MA, Olarte JQ, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Schips L. Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World J Urol. 2018 Oct.37(8):1649-1657. Pubmedid: 30377813.
      • Zargar-Shoshtari K, Sharma P, Spiess PE. Insight into novel biomarkers in penile cancer: Redefining the present and future treatment paradigm?. Urol Oncol. 2018 Oct.36(10):433-439. Pubmedid: 29103967.
      • Azizi M, Peyton CC, Spiess PE. Primitive neuroectodermal tumor arising from an untreated congenital undescended testicle. Can J Urol. 2018 Oct.25(5):9530-9533. Pubmedid: 30281013.
      • Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY. Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. BMC Anesthesiol. 2018 Nov.18(1):157. Pubmedid: 30390636. Pmcid: PMC6215353.
      • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
      • Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. J Urol. 2018 May.199(5):1129-1142. Pubmedid: 29113841.
      • Baumgarten A, Chipollini J, Yan S, Ottenhof SR, Tang DH, Draeger D, Protzel C, Zhu Y, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. J Urol. 2018 May.199(5):1233-1237. Pubmedid: 29132984.
      • Chipollini J, Yan S, Ottenhof SR, Zhu Y, Draeger D, Baumgarten AS, Tang DH, Protzel C, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Surgical management of penile carcinoma in situ: results from an international collaborative study and review of the literature. BJU Int. 2018 Mar.121(3):393-398. Pubmedid: 28972681.
      • Azizi M, Peyton CC, Boulware DC, Chipollini J, Juwono T, Pow-Sang JM, Spiess PE. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection. Eur Urol Focus. 2018 Jun.5(6):1085-1090. Pubmedid: 29937330. Pmcid: PMC7771277.
      • Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol. 2018 Jun.199(6):1452-1458. Pubmedid: 29329894.
      • Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
      • Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, Palapattu GS, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ. Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. Urology. 2018 Jul.117:95-100. Pubmedid: 29678662.
      • Attalla K, Paulucci DJ, Blum K, Anastos H, Moses KA, Badani KK, Spiess PE, Sfakianos JP. Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database. Urol Oncol. 2018 Jan.36(1):14.e17-14.e24. Pubmedid: 29031418.
      • Azizi M, Spiess PE. Penile cancer: Targeted therapy in penile cancer: a new treatment paradigm. Nat Rev Urol. 2018 Jan.15(1):5-6. Pubmedid: 29089608.
      • Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE. Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. Urol Oncol. 2018 Jan.36(1):14.e1-14.e5. Pubmedid: 29032883.
      • Tang DH, Chipollini J, Spiess PE. Postchemotherapy lymph node dissection for isolated retroperitoneal nodal recurrences for penile cancer: Is cure possible in highly selected cases?. Urol Oncol. 2018 Jan.36(1):1-3. Pubmedid: 29108682.
      • Chipollini J, Chaing S, Peyton CC, Sharma P, Kidd LC, Giuliano AR, Johnstone PA, Spiess PE. National Trends and Predictors of Locally Advanced Penile Cancer in the United States (1998-2012). Clin Genitourin Cancer. 2018 Feb.16(1):e121-e127. Pubmedid: 28866244.
      • Ottenhof SR, Leone A, Djajadiningrat RS, Azizi M, Zargar K, Kidd LC, Diorio G, Mosiello G, Graafland NM, Spiess PE, Horenblas S. Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus. 2018 Feb.5(5):867-874. Pubmedid: 29433986.
      • Kamel MH, Tao J, Su J, Khalil MI, Bissada NK, Schurhamer B, Spiess PE, Davis R. Survival outcomes of organ sparing surgery, partial penectomy, and total penectomy in pathological T1/T2 penile cancer: Report from the National Cancer Data Base. Urol Oncol. 2018 Feb.36(2):82.e7-82.e15. Pubmedid: 29153943.
      • Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol. 2018 Dec.37(10):2017-2029. Pubmedid: 30535583.
      • Marchioni M, Berardinelli F, De Nunzio C, Spiess P, Porpiglia F, Schips L, Cindolo L. New insight in penile cancer. Minerva Urol Nefrol. 2018 Dec.70(6):559-569. Pubmedid: 30230297.
      • Chipollini J, Necchi A, Spiess PE. Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. Eur Urol. 2018 Aug.74(2):241-242. Pubmedid: 29730019.
      • Mir MC, Matin SF, Bex A, Spiess PE, Thompson RH, Grob B, van Poppel H. The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urol Nefrol. 2018 Apr.70(2):109-125. Pubmedid: 29381020.
      • Tang DH, Yan S, Ottenhof SR, Draeger D, Baumgarten AS, Chipollini J, Protzel C, Zhu Y, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urol Oncol. 2018 Apr.36(4):147-152. Pubmedid: 29097087.
      • Chipollini J, Tang DH, Sharma P, Spiess PE. National Trends and Predictors of Organ-sparing for Invasive Penile Tumors: Expanding the Therapeutic Window. Clin Genitourin Cancer. 2018 Apr.16(2):e383-e389. Pubmedid: 28967504.
      • Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 Apr.16(2):e443-e450. Pubmedid: 29113770. Pmcid: PMC7771342.
      • Baumgarten AS, Fisher JS, Lawindy SM, Pavlinec JG, Carrion RE, Spiess PE. Penile sparing surgical approaches for primary penile tumors: preserving function and appearance. Transl Androl Urol. 2017 Oct.6(5):809-819. Pubmedid: 29184777. Pmcid: PMC5673820.
      • Tang DH, Djajadiningrat R, Diorio G, Chipollini J, Ma Z, Schaible BJ, Catanzaro M, Ye D, Zhu Y, Nicolai N, Horenblas S, Johnstone PAS, Spiess PE. Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urol Oncol. 2017 Oct.35(10):605.e17-605.e23. Pubmedid: 28666722. Pmcid: PMC7771352.
      • Spiess PE, Poch MA. Management of penile cancer. Transl Androl Urol. 2017 Oct.6(5):783-784. Pubmedid: 29184773. Pmcid: PMC5673816.
      • Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Oct.15(10):1240-1267. Pubmedid: 28982750.
      • Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Transl Androl Urol. 2017 Oct.6(5):791-802. Pubmedid: 29184775. Pmcid: PMC5673821.
      • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Nov.8(58):99093-99103. Pubmedid: 29228755. Pmcid: PMC5716795.
      • Ottenhof SR, Leone AR, Horenblas S, Spiess PE, Vegt E. Advancements in staging and imaging for penile cancer. Curr Opin Urol. 2017 Nov.27(6):612-620. Pubmedid: 28937510.
      • Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshmand S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W. Dose dense MVAC prior to radical cystectomy: a real-world experience. World J Urol. 2017 Nov.35(11):1729-1736. Pubmedid: 28625005.
      • Tang DH, Yan S, Ottenhof SR, Draeger D, Baumgarten AS, Chipollini J, Protzel C, Zhu Y, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology. 2017 Nov.109:140-144. Pubmedid: 28818536.
      • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May.103:142-148. Pubmedid: 28011275.
      • Lewis KM, Li Q, Jones DS, Corrales JD, Du H, Spiess PE, Lo Menzo E, DeAnda A. Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017 Mar.161(3):771-781. Pubmedid: 27839931.
      • Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017 Mar.35(3):379-387. Pubmedid: 27604375.
      • Leone A, Diorio GJ, Pettaway C, Master V, Spiess PE. Contemporary management of patients with penile cancer and lymph node metastasis. Nat Rev Urol. 2017 Jun.14(6):335-347. Pubmedid: 28401957.
      • Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul.105:108-112. Pubmedid: 28342928.
      • McCormick B, Dahmen A, Antar A, Baumgarten A, Dhillon J, Spiess PE. Rare urologic tumors. Curr Opin Urol. 2017 Jan.27(1):68-75. Pubmedid: 27798414.
      • Leone AR, Kidd LC, Diorio GJ, Zargar-Shoshtari K, Sharma P, Sexton WJ, Spiess PE. Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review. BMC Urol. 2017 Jan.17(1):6. Pubmedid: 28081704. Pmcid: PMC5234146.
      • Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol. 2017 Feb.197(2):287-295. Pubmedid: 27664578.
      • Spiess PE, Diorio GJ. Editorial Comment. J Urol. 2017 Feb.197(2):396-397. Pubmedid: 27836457.
      • Thomas K, Spiess P, Caracciolo JT. A report of two deep-seated noncutaneous penile tumors: more than meets the eye. Radiol Case Rep. 2017 Dec.12(4):726-730. Pubmedid: 29484058. Pmcid: PMC5823293.
      • Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 Dec.15(6):696-703. Pubmedid: 28566202.
      • Chipollini J, Tang DH, Sharma P, Baumgarten AS, Spiess PE. Patterns of Regional Lymphadenectomy for Clinically Node-negative Patients With Penile Carcinoma: Analysis From the National Cancer Database From 1998 to 2012. Clin Genitourin Cancer. 2017 Dec.15(6):670-677.e1. Pubmedid: 28522287.
      • Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol. 2017 Dec.198(6):1346-1352. Pubmedid: 28652123.
      • Ordookhanian C, Kaloostian PE, Ghostine SS, Spiess PE, Etame AB. Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas. J Kidney Cancer VHL. 2017 Aug.4(3):37-44. Pubmedid: 28868236. Pmcid: PMC5573741.
      • Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Aug.198(2):281-288. Pubmedid: 28268170.
      • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug.15(4):e583-e589. Pubmedid: 28410909. Pmcid: PMC7771283.
      • Chipollini J, Chaing S, Azizi M, Kidd LC, Kim P, Spiess PE. Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets. Int J Mol Sci. 2017 Aug.18(8). Pubmedid: 28813024. Pmcid: PMC5578166.
      • Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr.35(4):657-663. Pubmedid: 27495912.
      • Leone A, Inman B, Spiess PE. Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors. Eur Urol. 2017 07.72(1):4-6. Pubmedid: 28131464.
      • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 05.103:148. Pubmedid: 28108090.
      • Sharma P, Zargar-Shoshtari K, Pettaway CA, Schabath MB, Giuliano AR, Spiess PE. Disparities in Penile Cancer. Cancer Control. 2016 Oct.23(4):409-414. Pubmedid: 27842330.
      • Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM. Chemoprevention in African American Men With Prostate Cancer. Cancer Control. 2016 Oct.23(4):415-423. Pubmedid: 27842331.
      • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct.7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
      • Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Ne. 2016 Oct.14(10):1213-1224. Pubmedid: 27697976. Pmcid: PMC5379654.
      • Diorio GJ, Leone AR, Spiess PE. Management of Penile Cancer. Urology. 2016 Oct.96:15-21. Pubmedid: 26802797.
      • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov.34(11):1567-1573. Pubmedid: 27072536.
      • Spiess PE. Penile, Urethral, and Scrotal Cancer. Urol Clin North Am. 2016 Nov.43(4):xvii-xviii. Pubmedid: 27717442.
      • Spiess PE, Dhillon J, Baumgarten AS, Johnstone PA, Giuliano AR. Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. CA-Cancer J Clin. 2016 Nov.66(6):481-495. Pubmedid: 27314890.
      • Sharma P, Zargar H, Spiess PE. Surgical Advances in Inguinal Lymph Node Dissection: Optimizing Treatment Outcomes. Urol Clin North Am. 2016 Nov.43(4):457-468. Pubmedid: 27717432.
      • Zargar-Shoshtari K, Zargar H, Dinney CP, Ercole CE, Sharma P, Kovac E, Grivas PD, Stephenson AJ, Shah JB, Black PC, Spiess PE. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World J Urol. 2016 May.34(5):695-701. Pubmedid: 26286880.
      • Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar.34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
      • Sharma P, Ashouri K, Zargar-Shoshtari K, Luchey AM, Spiess PE. Racial and economic disparities in the treatment of penile squamous cell carcinoma: Results from the National Cancer Database. Urol Oncol. 2016 Mar.34(3):122.e9-122.15. Pubmedid: 26547834.
      • Zargar-Shoshtari K, Sharma P, Djajadiningrat R, Catanzaro M, Ye DW, Zhu Y, Nicolai N, Horenblas S, Spiess PE. Extent of pelvic lymph node dissection in penile cancer may impact survival. World J Urol. 2016 Mar.34(3):353-359. Pubmedid: 26026817.
      • Leone AR, Diorio GJ, Spiess PE, Gilbert SM. Contemporary Issues Surrounding Small Renal Masses: Evaluation, Diagnostic Biopsy, Nephron Sparing, and Novel Treatment Modalities. Oncology (Williston Park). 2016 Jun.30(6):507-514. Pubmedid: 27323710.
      • Russell CM, Lue K, Fisher J, Kassouf W, Schwaab T, Sexton WJ, Tanguay S, Psutka SP, Thompson RH, Leibovich BC, Hanzly MI, Spiess PE, Boorjian SA. Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. BJU Int. 2016 Jun.117(6B):E60-E66. Pubmedid: 26118331.
      • Leone A, Diorio G, Zargar-Shoshtari K, Spiess PE. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Transl Androl Urol. 2016 Jun.5(3):393-395. Pubmedid: 27296873. Pmcid: PMC4893515.
      • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul.93:130-134. Pubmedid: 27041469.
      • Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan.195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
      • Fisher JS, Gonzalez R, Spiess PE. A Novel Use of Tisseel in the Setting of Uncontrolled Bleeding in a Thrombocytopenic Patient With Idiopathic Thrombocytopenia. Urol Case Rep. 2016 Jan.4:48-50. Pubmedid: 26793579. Pmcid: PMC4719898.
      • Dickey RM, Srikishen N, Lipshultz LI, Spiess PE, Carrion RE, Hakky TS. Augmented reality assisted surgery: a urologic training tool. Asian J Androl. 2016 Jan.18(5):732-734. Pubmedid: 26620455. Pmcid: PMC5000796.
      • Zargar-Shoshtari K, Zargar H, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. J Urol. 2016 Jan.195(1):53-59. Pubmedid: 26205531.
      • Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2016 Feb.14(1):82-88. Pubmedid: 26411593.
      • Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?. Can J Urol. 2016 Feb.23(1):8127-8134. Pubmedid: 26892052.
      • Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clin Genitourin Cancer. 2016 Feb.14(1):89-95. Pubmedid: 26453395.
      • Gwede CK, Davis SN, Wilson S, Patel M, Vadaparampil ST, Meade CD, Rivers BM, Yu D, Torres-Roca J, Heysek R, Spiess PE, Pow-Sang J, Jacobsen P. Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. Am J Health Promot. 2016 Dec.29(6):393-401. Pubmedid: 24968183. Pmcid: PMC4277494.
      • Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE. Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. ANZ J Surg. 2016 Dec.86(1-2):44-48. Pubmedid: 26370725.
      • Zargar-Shoshtari K, Spiess PE, Berglund AE, Sharma P, Powsang JM, Giuliano A, Magliocco AM, Dhillon J. Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort. Clin Genitourin Cancer. 2016 Aug.14(4):346-351. Pubmedid: 26794389. Pmcid: PMC7771549.
      • Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urol Ann. 2016 Apr.8(2):151-156. Pubmedid: 27141183. Pmcid: PMC4839230.
      • Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?. J Urol. 2016 Apr.195(4 Pt 1):886-893. Pubmedid: 26521718.
      • Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE. Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. Int Braz J Urol. 2015 Sep.41(5):911-919. Pubmedid: 26689516. Pmcid: PMC4756967.
      • Gonzalez BD, Jim HS, Donovan KA, Small BJ, Sutton SK, Park J, Lin HY, Spiess PE, Fishman MN, Jacobsen PB. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. J Urol. 2015 Sep.194(3):690-695. Pubmedid: 25791402. Pmcid: PMC4546512.
      • Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE. Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL. 2015 Sep.2(4):163-173. Pubmedid: 28326271. Pmcid: PMC5345519.
      • Zargar-Shoshtari K, Djajadiningrat R, Sharma P, Catanzaro M, Zhu Y, Nicolai N, Horenblas S, Spiess PE. Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. J Urol. 2015 Sep.194(3):696-701. Pubmedid: 25801766.
      • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Oct.33(10):1585-1592. Pubmedid: 25552207.
      • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct.8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
      • Sharma P, Sawar A, Spiess P. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8. Eur Urol. 2015 Oct.68(4):e79-e80. Pubmedid: 26007640.
      • Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov.194(5):1220-1225. Pubmedid: 26055823.
      • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Nov.33(11):1763-1768. Pubmedid: 25774005.
      • Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, Sexton WJ, Spiess PE. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol. 2015 Mar.33(3):112.e23-112.e29. Pubmedid: 25555854.
      • Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, Park JY, Spiess PE, Fishman MN, Jacobsen PB. Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol. 2015 Jun.33(18):2021-2027. Pubmedid: 25964245. Pmcid: PMC4461804.
      • Abarzua-Cabezas FG, Sverrisson E, Cruz Rde L, Spiess PE, Haddock P, Sexton WJ. Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol. 2015 Jun.41(1):147-154. Pubmedid: 25928521. Pmcid: PMC4752068.
      • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun.13(3):225-230. Pubmedid: 25544725.
      • Zargar-Shoshtari K, Sharma P, Spiess PE. Re: Oliver W. Hakenberg, Eva M. Compérat, Suks Minhas, Andrea Necchi, Chris Protzel, Nick Watkin. EAU Guidelines on Penile Cancer: 2014 Update. Eur Urol 2015;67:142-50. Eur Urol. 2015 Jun.67(6):e109-e110. Pubmedid: 25530609.
      • Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb.67(2):241-249. Pubmedid: 25257030. Pmcid: PMC4840190.
      • Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol. 2015 Dec.194(6):1567-1574. Pubmedid: 26094807. Pmcid: PMC4896731.
      • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug.33(8):339.e17-339.e23. Pubmedid: 26094169.
      • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2015 Aug.116(2):196-201. Pubmedid: 25777366.
      • Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. Urology. 2015 Aug.86(2):321-326. Pubmedid: 26187013.
      • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug.22(4):7882-7889. Pubmedid: 26267026.
      • Sharma P, Spiess PE. Penile cancer: Advanced penile cancer continues to elude systemic therapy. Nat Rev Urol. 2015 Apr.12(4):185-186. Pubmedid: 25708580.
      • Sharma P, Zargar-Shoshtari K, Spiess PE. Current surgical management of penile cancer. Curr Prob Cancer. 2015 Apr.39(3):147-157. Pubmedid: 25913491.
      • Baumgarten AS, Alhammali E, Hakky TS, Espiritu PN, Pow-Sang JM, Sexton WJ, Lockhart JL, Protzel C, Hakenberg O, Muneer A, Spiess PE. Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration. J Urol. 2014 Sep.192(3):760-764. Pubmedid: 24603104.
      • Zhao Y, Bui MM, Spiess PE, Dhillon J. Sclerosing PEComa of the kidney: clinicopathologic analysis of 2 cases and review of the literature. Clin Genitourin Cancer. 2014 Oct.12(5):e229-e232. Pubmedid: 25044147.
      • Armstrong PA, Back MR, Shames ML, Bailey CJ, Kim T, Lawindy SM, Sexton WJ, Spiess PE. Outcomes after inferior vena cava thrombectomy and reconstruction for advanced renal cell carcinoma with tumor thrombus. J Vasc Surg Venous Lymphat Disord. 2014 Oct.2(4):368-376. Pubmedid: 26993539.
      • Davis SN, Sutton SK, Vadaparampil ST, Meade CD, Rivers BM, Patel MV, Torres-Roca JF, Heysek RV, Spiess P, Pow-Sang J, Jacobsen PB, Gwede CK. Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial. Contemp Clin Trials. 2014 Nov.39(2):327-334. Pubmedid: 25465497. Pmcid: PMC4274628.
      • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul.32(5):619-624. Pubmedid: 24495448.
      • Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 2014 Jul. Pubmedid: 24893916.
      • Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, Spiess PE. Implications for human papillomavirus in penile cancer. Urol Oncol. 2014 Jan.32(1):53.e1-53.e8. Pubmedid: 24239463.
      • Dhillon J, Mohanty SK, Kim T, Sexton WJ, Powsang J, Spiess PE. Spectrum of renal pathology in adult patients with congenital renal anomalies-a series from a tertiary cancer center. Ann Diagn Pathol. 2014 Feb.18(1):14-17. Pubmedid: 24321461.
      • Hakky TS, Baumgarten AS, Allen B, Lin HY, Ercole CE, Sexton WJ, Spiess PE. Zonal NePhRO scoring system: a superior renal tumor complexity classification model. Clin Genitourin Cancer. 2014 Feb.12(1):e13-e18. Pubmedid: 24120084.
      • Hegarty PK, Eardley I, Heidenreich A, McDougal WS, Minhas S, Spiess PE, Watkin N, Horenblas S. Penile cancer: organ-sparing techniques. BJU Int. 2014 Dec.114(6):799-805. Pubmedid: 24053403.
      • Zheng Y, Espiritu P, Hakky T, Jutras K, Spiess PE. Predicting ease of perinephric fat dissection at time of open partial nephrectomy using preoperative fat density characteristics. BJU Int. 2014 Dec.114(6):872-880. Pubmedid: 24274617.
      • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug.192(2):350-356. Pubmedid: 24530987.
      • Agarwal G, Gupta S, Spiess PE. Novel targeted therapies for the treatment of penile cancer. Expert Opin Drug Discov. 2014 Aug.9(8):959-968. Pubmedid: 24896220.
      • Baumgarten AS, Emtage JB, Wilder RB, Biagioli MC, Gupta S, Spiess PE. Intravesical lipiodol injection technique for image-guided radiation therapy for bladder cancer. Urology. 2014 Apr.83(4):946-950. Pubmedid: 24397940.
      • Spiess PE. Reply: To PMID 24397943. Urology. 2014 Apr.83(4):950. Pubmedid: 24397942.
      • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014 Apr.111(1):126-131. Pubmedid: 24746567.
      • Wallen JJ, Baumgarten AS, Kim T, Hakky TS, Carrion RE, Spiess PE. Optimizing penile length in patients undergoing partial penectomy for penile cancer: novel application of the ventral phalloplasty oncoplastic technique. Int Braz J Urol. 2014.40(5):708-709. Pubmedid: 25498284.
      • Protzel C, Spiess PE. Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?. Int J Mol Sci. 2013 Sep.14(10):19494-19505. Pubmedid: 24077122. Pmcid: PMC3821569.
      • Agarwal G, Spiess PE. Prostate cancer: Focal cryotherapy freezes recurrent disease in its tracks. Nat Rev Urol. 2013 Oct.10(10):562-563. Pubmedid: 23979660.
      • Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol. 2013 Oct.5(5):223-232. Pubmedid: 24082917. Pmcid: PMC3763778.
      • Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Current concepts in penile cancer. J Natl Compr Canc Ne. 2013 May.11(5):617-624. Pubmedid: 23667210.
      • Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2013 May.11(5):594-615. Pubmedid: 23667209. Pmcid: PMC4042432.
      • Spiess PE. New treatment guidelines for penile cancer. J Natl Compr Canc Ne. 2013 May.11(5 Suppl):659-662. Pubmedid: 23704237.
      • Sverrisson EF, Espiritu PN, Spiess PE. New therapeutic targets in the management of urothelial carcinoma of the bladder. Res Rep Urol. 2013 Mar.5:53-65. Pubmedid: 24400235. Pmcid: PMC3826897.
      • Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control. 2013 Jul.20(3):188-199. Pubmedid: 23811703.
      • Ercole CE, Pow-Sang JM, Spiess PE. Update in the surgical principles and therapeutic outcomes of inguinal lymph node dissection for penile cancer. Urol Oncol. 2013 Jul.31(5):505-516. Pubmedid: 21481617.
      • Buethe DD, Spiess PE. Current management considerations for the incidentally detected small renal mass. Cancer Control. 2013 Jul.20(3):211-221. Pubmedid: 23811705.
      • Hakky TS, Ferguson D, Spiess PE, Bradley P, Lue TF, Carrion RE. Three-dimensional mapping and comparative analysis of the distal human corpus cavernosum and the inflatable penile prosthesis. Asian J Androl. 2013 Jul.15(4):567-570. Pubmedid: 23542138. Pmcid: PMC3739224.
      • Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS One. 2013 Jan.7(8):e42452. Pubmedid: 22879988. Pmcid: PMC3411788.
      • Spiess PE. Editor's Comment. Int Braz J Urol. 2013 Jan.39(1):1-3. Pubmedid: 23489511.
      • Spiess PE, Levy DA, Pisters LL, Mouraviev V, Jones JS. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. World J Urol. 2013 Dec.31(6):1321-1325. Pubmedid: 23179729.
      • Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int. 2013 Aug.112(4):E256-E261. Pubmedid: 23469778.
      • Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Ne. 2013 Apr.11(4):446-475. Pubmedid: 23584347.
      • Buethe DD, Moussly S, Lin HY, Yue B, Rodriguez AR, Spiess PE, Sexton WJ. Is the R.E.N.A.L. nephrometry scoring system predictive of the functional efficacy of nephron sparing surgery in the solitary kidney?. J Urol. 2012 Sep.188(3):729-735. Pubmedid: 22819418.
      • Spiess PE, Buethe D. Reply. BJU Int. 2012 Oct.110(7):E328. Pubmedid: 22954032.
      • Lawindy SM, Kurian T, Kim T, Mangar D, Armstrong PA, Alsina AE, Sheffield C, Sexton WJ, Spiess PE. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int. 2012 Oct.110(7):926-939. Pubmedid: 22540179.
      • Rodriguez AR, Spiess PE. Editorial comment for Park et al. J Endourol. 2012 May.26(5):498. Pubmedid: 22214182.
      • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar.2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
      • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar.33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
      • Mouraviev V, Spiess PE, Jones JS. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol. 2012 Jun.61(6):1204-1211. Pubmedid: 22421081.
      • Spiess PE, Given RW, Jones JS. Achieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) registry data. BJU Int. 2012 Jul.110(2):217-220. Pubmedid: 21992443.
      • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan.2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
      • Hakky T, Kim T, Rodriguez AR, Armstrong P, Mangar D, Spiess PE. Retroperitoneal lymph node dissection with concomitant IVC thrombectomy, caval wall resection, and grafting for metastatic NSGCT. Int Braz J Urol. 2012 Jan.38(1):135. Pubmedid: 22397783.
      • Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec.110(11 Pt B):E470-E474. Pubmedid: 22519938.
      • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec.110(11 Pt B):E475-E480. Pubmedid: 22564727.
      • Kolla SB, Spiess PE, Sexton WJ. Interobserver reliability of the RENAL nephrometry scoring system. Urology. 2011 Sep.78(3):592-594. Pubmedid: 21782219.
      • Torrey R, Spiess PE, Pal SK, Josephson D. Role of surgery for locally advanced and metastatic renal cell carcinoma. J Natl Compr Canc Ne. 2011 Sep.9(9):985-993. Pubmedid: 21917623.
      • Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Ne. 2011 Sep.9(9):960-977. Pubmedid: 21917622.
      • Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal. 2011 May.11:1103-1112. Pubmedid: 21623456. Pmcid: PMC5720052.
      • Lawindy SM, Rodriguez AR, Horenblas S, Spiess PE. Current and future strategies in the diagnosis and management of penile cancer. Adv Urol. 2011 Jul.2011:593751. Pubmedid: 21687574. Pmcid: PMC3113410.
      • Wiegand LR, Hernandez M, Pisters LL, Spiess PE. Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int. 2011 Apr.107(8):1238-1242. Pubmedid: 20880197.
      • Spiess PE, Fishman MN. Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma. Cancer Control. 2010 Oct.17(4):269-278. Pubmedid: 20861814.
      • Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov.106(10):1494-1498. Pubmedid: 20230378.
      • Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen-Engquist KM. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol. 2010 May.28(13):2274-2279. Pubmedid: 20368572. Pmcid: PMC2860440.
      • Childs MA, Wood CG, Spiess PE, Debiane LG, Hernandez M, Matin SF, Millikan RE, Siefker-Radtkie A, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol. 2010 Jun.17(3):5184-5189. Pubmedid: 20566011.
      • Spiess PE. Editorial comment. Urology. 2010 Jun.75(6):1410-1411. Pubmedid: 20513502.
      • Spiess PE. Surgical management of locally recurrent renal cell carcinoma post-renal cryoablation: importance of stringent selection criteria. Urol Oncol. 2010 Jul.28(3):241-242. Pubmedid: 20189841.
      • Parker J, Buga S, Sarria JE, Spiess PE. Advancements in the management of urologic chronic pelvic pain: what is new and what do we know?. Curr Urol Rep. 2010 Jul.11(4):286-291. Pubmedid: 20449695.
      • Spiess PE, Katz AE, Chin JL, Bahn D, Cohen JK, Shinohara K, Hernandez M, Bossier J, Kassouf W, Pisters LL. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int. 2010 Jul.106(2):194-198. Pubmedid: 19922545.
      • Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul.106(1):56-61. Pubmedid: 20002676.
      • Correa JJ, Hakky TS, Spiess PE, Chuang T, Sexton WJ. Robotic-assisted partial cystectomy with en bloc excision of the urachus and the umbilicus for urachal adenocarcinoma. J Robot Surg. 2010 Jan.3(4):235-238. Pubmedid: 27628636.
      • Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urology. 2009 Sep.182(3):887-893. Pubmedid: 19616230.
      • Correa JJ, Fishman M, Chuang ST, Spiess PE. Surgery plus targeted therapy for renal cell carcinoma with isolated spermatic cord metastasis. Clin Genitourin Cancer. 2009 Oct.7(3):E101-E103. Pubmedid: 19815479.
      • Spiess PE. "Robotic cystectomy and the internet: separating fact from fiction" by Pruthi R.S. et al. Urol Oncol. 2009 Nov.27(6):686. Pubmedid: 19879480.
      • Svatek R, Spiess P, Sundi D, Tu S, Tannir N, Brown G, Kamat A, Wood C, Pisters L. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar.115(6):1310-1317. Pubmedid: 19156903.
      • Spiess P, Pisters L, Liu P, Pettaway C, Kamat A, Gomez J, Tannir N. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol. 2009 Jan.26(6):595-599. Pubmedid: 18367105. Pmcid: PMC4121060.
      • Williams DH 4th, Karpman E, Sander J, Spiess P, Pisters L, Lipshultz L. Pretreatment semen parameters in men with cancer. J Urol. 2009 Feb.181(2):736-740. Pubmedid: 19091343.
      • Svatek RS, Munsell M, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston KE, Spiess PE, Pagliaro LC, Tamboli P, Pettaway CA. Association between lymph node density and disease specific survival in patients with penile cancer. J Urol. 2009 Dec.182(6):2721-2727. Pubmedid: 19837433.
      • Gorbatiy V, Spiess PE, Pisters LL. The growing teratoma syndrome: Current review of the literature. Indian J Urol. 2009 Apr.25(2):186-189. Pubmedid: 19672343. Pmcid: PMC2710061.
      • Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol. 2009 Apr.27(2):205-212. Pubmedid: 18762945.
      • Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate. 2008 Sep.68(13):1467-1476. Pubmedid: 18618693. Pmcid: PMC2574568.
      • Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008 Oct.100(19):1401-1411. Pubmedid: 18812553. Pmcid: PMC2720731.
      • Kassouf W, Spiess P, Brown G, Liu P, Grossman H, Dinney C, Kamat A. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul.180(1):164-167. Pubmedid: 18485384. Pmcid: PMC5154171.
      • Kassouf W, Agarwal P, Herr H, Munsell M, Spiess P, Brown G, Pisters L, Grossman H, Dinney C, Kamat A. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan.26(1):121-126. Pubmedid: 18165646.
      • Leibovici D, Spiess P, Heller L, Rodriguez-Bigas M, Chang G, Pisters L. Salvage surgery for locally recurrent prostate cancer after radiation therapy: tricks of the trade. Urol Oncol. 2008 Jan.26(1):9-16. Pubmedid: 18190824.
      • Spiess P, Busby J, Jordan J, Steinberg J, Bassett R, Davuluri R, Burt K, Troncoso P, Lee A, Taylor S, Pisters L. Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer?. Urol Oncol. 2008 Feb.26(1):25-30. Pubmedid: 18190826.
      • Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep.52(3):769-774. Pubmedid: 17434254. Pmcid: PMC2691552.
      • Spiess P, Pettaway C, Vakar-Lopez F, Kassouf W, Wang X, Busby J, Do K, Davuluri R, Tannir N. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007 Oct.110(8):1729-1737. Pubmedid: 17786954.
      • Spiess P, Tuziak T, Tibbs R, Bassett R, Tamboli P, Brown G, Grossman H, Ayala A, Czerniak B. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol. 2007 May.38(5):753-761. Pubmedid: 17306332.
      • Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant M, Spiess P, WoodCG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology. 2007 May.69(5):835-838. Pubmedid: 17482917.
      • Zorn K, Spiess P, Singh G, Orvieto M, Moore B, Corcos J. Long-term tensile properties of tension-free vaginal tape, suprapubic arc sling system and urethral sling in an in vivo rat model. J Urology. 2007 Mar.177(3):1195-1198. Pubmedid: 17296444.
      • Spiess P, Izawa J, Bassett R, Kedar D, Busby J, Wong F, Eddings T, TamboliP, Pettaway C. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol. 2007 Jun.177(6):2157-2161. Pubmedid: 17509308.
      • Tuziak T, Spiess P, Abrahams N, Wrona A, Tu S, Czerniak B. Multilocular cystadenoma and cystadenocarcinoma of the prostate. Urol Oncol. 2007 Jan.25(1):19-25. Pubmedid: 17208134.
      • Spiess P, Brown G, Liu P, Tu S, Tannir N, Evans J, Kamat A, Kassouf W, Pisters L. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urology. 2007 Jan.177(1):131-138. Pubmedid: 17162023.
      • Leibovici D, Spiess P, Agarwal P, Tu S, Pettaway C, Hitzhusen K, MillikanRE, Pisters L. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan.109(2):198-204. Pubmedid: 17171704.
      • Spiess P, Kassouf W, Steinberg J, Tuziak T, Hernandez M, Tibbs R, CzerniakB, Kamat A, Dinney C, Grossman H. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan.25(1):38-45. Pubmedid: 17208137.
      • Spiess P, Lee A, Busby J, Jordan J, Hernandez M, Burt K, Troncoso P, Merriman K, Pisters L. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome. Bju Int. 2007 Feb.99(2):321-325. Pubmedid: 17155975.
      • Spiess P, Tannir N, Brown G, Liu P, Tu S, Evans J, Pisters L. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec.70(6):1173-1178. Pubmedid: 18158041.
      • Spiess P, Tannir N, Tu S, Brown G, Liu P, Kamat A, Wood C, Evans J, Pisters L. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression. Cancer. 2007 Dec.110(12):2700-2708. Pubmedid: 17948916.
      • Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug.110(4):764-769. Pubmedid: 17614317.
      • Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci U S A. 2007 Aug.104(34):13732-13737. Pubmedid: 17702869. Pmcid: PMC1949496.
      • Bermejo C, Busby J, Spiess P, Heller L, Pagliaro L, Pettaway C. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urology. 2007 Apr.177(4):1335-1338. Pubmedid: 17382727.
      • Shinn EH, Basen-Engquist K, Thornton B, Spiess PE, Pisters L. Health behaviors and depressive symptoms in testicular cancer survivors. Urology. 2007 Apr.69(4):748-753. Pubmedid: 17445663. Pmcid: PMC2674069.
      • Spiess P, Kassouf W, Brown G, Kamat A, Liu P, Gomez J, Tu S, Tannir N, Pisters L. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urology. 2007 Apr.177(4):1330-1334. Pubmedid: 17382725.
      • Spiess P, Grossman H. Fluorescence cystoscopy: is it ready for use in routine clinical practice?. Curr Opin Urol. 2006 Sep.16(5):372-376. Pubmedid: 16905985.
      • Spiess P, Brown G, Liu P, Tannir N, Tu S, Evans J, Czerniak B, Kamat A, Pisters L. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct.107(7):1483-1490. Pubmedid: 16944541.
      • Spiess P, Brown G, Pisters L, Liu P, Tu S, Evans J, Kamat A, Black P, Tannir N. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?. Cancer. 2006 Oct.107(7):1503-1510. Pubmedid: 16944534.
      • Evans J, Spiess P, Kamat A, Wood C, Hernandez M, Pettaway C, Dinney C, Pisters L. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urology. 2006 Oct.176(4 Pt 1):1463-1467. Pubmedid: 16952661.
      • Spiess P, Leibovici D, Pisters L. Surgery for locally advanced disease. Curr Urol Rep. 2006 May.7(3):209-216. Pubmedid: 16630524.
      • Spiess P, Kassouf W, Brown G, Highshaw R, Wang X, Do K, Kamat A, CzerniakB, Dinney C, Grossman H. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. Urology. 2006 Mar.67(3):466-471. Pubmedid: 16527559.
      • Zorn K, Spiess P, Ross P, Taguchi Y, Aprikian A. Resident involvement in open radical prostatectomy: a review of urology surgical training. Can J Urol. 2006 Jun.13(3):3164-3168. Pubmedid: 16813710.
      • Spiess P, Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med. 2006 Jun.130(6):844-852. Pubmedid: 16740038.
      • Spiess P, Lee A, Leibovici D, Wang X, Do K, Pisters L. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006 Jul.107(2):275-280. Pubmedid: 16770783.
      • Taylor S, Merriman K, Spiess P, Pisters L. Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer. Cancer. 2006 Feb.106(3):559-565. Pubmedid: 16369982.
      • Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006 Aug.12(15):4671-4677. Pubmedid: 16899617.
      • Spiess P, Kassouf W, Tukaram K, Roy I. Metastatic umbilical mass from transitional cell carcinoma of the bladder. Can J Urol. 2005 Oct.12(5):2856-2858. Pubmedid: 16274525.
      • Leibovici D, Lee A, Cheung R, Spiess P, Kuban D, Rosser C, Shen Y, YangY, Chichakli R, Pisters L. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005 May.103(10):2060-2066. Pubmedid: 15822114.
      • Spiess P, Tuziak T, Kassouf W, Grossman H, Czerniak B. Malignant mesothelioma of the tunica vaginalis. Urology. 2005 Aug.66(2):397-401. Pubmedid: 16040098.
      • Zorn K, Spiess P, Salle J, Jednak R. Mucocolpos associated with bladder exstrophy: a case report. Can J Urol. 2005 Apr.12(2):2614-2615. Pubmedid: 15877945.
      • Spiess P, Rabah D, Herrera C, Singh G, Moore R, Corcos J. The tensile properties of tension-free vaginal tape and cadaveric fascia lata in an in vivo rat model. Bju Int. 2004 Jan.93(1):171-173. Pubmedid: 14678391.
      • Rabah D, Spiess P, Begin L, Corcos J. Tissue reaction of the rabbit urinary bladder to tension-free vaginal tape and porcine small intestinal submucosa. Bju Int. 2002 Oct.90(6):601-606. Pubmedid: 12230625.
      • Spiess P, Capolicchio J, Kiruluta G, Salle J, Berardinucci G, Corcos J. Is an artificial sphincter the best choice for incontinent boys with Spina Bifida? Review of our long term experience with the AS-800 artificial sphincter. Can J Urol. 2002 Apr.9(2):1486-1491. Pubmedid: 12010593.
      • Nam R, Redelmeier D, Spiess P, Sampson H, Fradet Y, Jewett M. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urology. 2000 Mar.1(3):752-757. Pubmedid: 10687970.
      • Spiess P, Dion S, Zvara P, Merlin S, Chan P, Brock G. 7-Nitroindazole: a selective inhibitor of penile erection: an in vivo study in a rat animal model. Urology. 1996 Jan.47(1):93-96. Pubmedid: 8560670 .
      • Zvara P, Spiess P, Merlin S, Begin L, Brock G. Neurogenic erectile dysfunction: the course of nicotinamide adenine dinucleotide phosphate diaphorase-positive nerve fibers on the surface of the prostate. Urology. 1996 Jan.47(1):146-151. Pubmedid: 8560654 .
      • Freilich JM, Spiess PE, Biagioli MC, Fernandez DC, Shi EJ, Hunt DC, Gupta S, Wilder RB. Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer. Int Braz J Urol. 40(2):190-197. Pubmedid: 24856485.
      • Hakky TS, Espiritu P, Rodriguez AR, Gould N, Spiess PE. Surgical management of a locally advanced symptomatic recurrence of penile sarcoma secondary to prostate brachytherapy. Int Braz J Urol. 39(2):293-294. Pubmedid: 23683678.
      • Spiess PE. Editor's Comment - Best videos of the year for the International Brazilian Journal of Urology 2014. Int Braz J Urol. 41(3):406-407. Pubmedid: 26200532. Pmcid: PMC4752130.
      • Sverrisson EF, Kim T, Espiritu PN, Sexton WJ, Pow-Sang JM, Dhillon J, Spiess PE. The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue. Int Braz J Urol. 40(4):493-498. Pubmedid: 25251966.
      • Spiess PE, Tannir NM. Reply. Urol Oncol. 27(2):218-219. Pubmedid: 19285239.
      • Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?. Int Braz J Urol. 36(5):571-582. Pubmedid: 21044374.
      • Spiess PE. Transurethral neo-orifice (TUNO) approach to managing upper pole renal obstruction. Int Braz J Urol. 40(1):1-2. Pubmedid: 24642145.
      • Spiess PE. Best videos of the year in 2017. Int Braz J Urol. 44(1):2-3. Pubmedid: 29424505. Pmcid: PMC5815525.
      • Tang DH, Spiess PE. Should routine neonatal circumcision be a policy to prevent penile cancer? | Opinion: No. Int Braz J Urol. 43(1):10-12. Pubmedid: 28124520. Pmcid: PMC5293377.
      • Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 40(5):637-643. Pubmedid: 25498274.
      • Spiess PE. Editorial Comment: Lapar oscopic radical nephrectomy with inferior vena cava thrombectomy: highlight of key surgical steps. Int Braz J Urol. 42(4):858. Pubmedid: 27564307. Pmcid: PMC5006792.
      • Spiess PE, Correa JJ. Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma. Int Braz J Urol. 35(5):609. Pubmedid: 19860941.
      • Rodriguez AR, Hakky T, Spiess PE. Laparo-endoscopic single site retroperitoneal partial nephrectomy: a novel concept. Int Braz J Urol. 37(1):136. Pubmedid: 21506441.
      • Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE. A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol. 40(2):225-231. Pubmedid: 24856490.
      • Caso JR, Rodriguez AR, Correa J, Spiess PE. Update in the management of penile cancer. Int Braz J Urol. 35(4):406-415. Pubmedid: 19719855.
      • Spiess PE. Selection of best videos of the year for 2016. Int Braz J Urol. 43(2):182-183. Pubmedid: 28328185. Pmcid: PMC5433353.
    • Grants

      • Title: Advancements in HPV-related Penile Cancer
        Sponsor: Evans Fdtn.
        PI: Spiess, P.

    Find a Researcher Search